<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30193098</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>03</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1097-4164</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>71</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>09</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular cell</Title>
          <ISOAbbreviation>Mol. Cell</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage.</ArticleTitle>
        <Pagination>
          <MedlinePgn>745-760.e5</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">S1097-2765(18)30603-8</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molcel.2018.07.034</ELocationID>
        <Abstract>
          <AbstractText>DNA damage can be sensed as a danger-associated molecular pattern by the innate immune system. Here we find that keratinocytes and other human cells mount an innate immune response within hours of etoposide-induced DNA damage, which involves the DNA sensing adaptor STING but is independent of the cytosolic DNA receptor cGAS. This non-canonical activation of STING is mediated by the DNA binding protein IFI16, together with the DNA damage response factors ATM and PARP-1, resulting in the assembly of an alternative STING signaling complex that includes the tumor suppressor p53 and the E3 ubiquitin ligase TRAF6. TRAF6 catalyzes the formation of K63-linked ubiquitin chains on STING, leading to the activation of the transcription factor NF-κB and the induction of an alternative STING-dependent gene expression program. We propose that STING acts as a signaling hub that coordinates a transcriptional response depending on its mode of activation.</AbstractText>
          <CopyrightInformation>Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dunphy</LastName>
            <ForeName>Gillian</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flannery</LastName>
            <ForeName>Sinéad M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Almine</LastName>
            <ForeName>Jessica F</ForeName>
            <Initials>JF</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Connolly</LastName>
            <ForeName>Dympna J</ForeName>
            <Initials>DJ</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paulus</LastName>
            <ForeName>Christina</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Sciences Research Complex, University of St Andrews, St Andrews KY16 9ST, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jønsson</LastName>
            <ForeName>Kasper L</ForeName>
            <Initials>KL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedicine, Aarhus University, Wilhelm Meyers Allé 4, 8000 Aarhus C, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jakobsen</LastName>
            <ForeName>Martin R</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedicine, Aarhus University, Wilhelm Meyers Allé 4, 8000 Aarhus C, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nevels</LastName>
            <ForeName>Michael M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Sciences Research Complex, University of St Andrews, St Andrews KY16 9ST, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bowie</LastName>
            <ForeName>Andrew G</ForeName>
            <Initials>AG</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Unterholzner</LastName>
            <ForeName>Leonie</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK. Electronic address: l.unterholzner@lancaster.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>MR/K00655X/1</GrantID>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AI093752</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>MR/P022146/1</GrantID>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Cell</MedlineTA>
        <NlmUniqueID>9802571</NlmUniqueID>
        <ISSNLinking>1097-2765</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C532857">Tmem173 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>148998-64-5</RegistryNumber>
          <NameOfSubstance UI="C076700">IFI16 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-49-2</RegistryNumber>
          <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.2.27</RegistryNumber>
          <NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.2.30</RegistryNumber>
          <NameOfSubstance UI="D000071137">Poly (ADP-Ribose) Polymerase-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C576324">ATM protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D064007">Ataxia Telangiectasia Mutated Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D064007" MajorTopicYN="N">Ataxia Telangiectasia Mutated Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015603" MajorTopicYN="N">Keratinocytes</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071137" MajorTopicYN="N">Poly (ADP-Ribose) Polymerase-1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">DNA damage</Keyword>
        <Keyword MajorTopicYN="Y">IFI16</Keyword>
        <Keyword MajorTopicYN="Y">STING</Keyword>
        <Keyword MajorTopicYN="Y">TRAF6</Keyword>
        <Keyword MajorTopicYN="Y">etoposide</Keyword>
        <Keyword MajorTopicYN="Y">innate immunity</Keyword>
        <Keyword MajorTopicYN="Y">interferon</Keyword>
        <Keyword MajorTopicYN="Y">p53</Keyword>
        <Keyword MajorTopicYN="Y">ubiquitin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>01</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>06</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>07</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30193098</ArticleId>
        <ArticleId IdType="pii">S1097-2765(18)30603-8</ArticleId>
        <ArticleId IdType="doi">10.1016/j.molcel.2018.07.034</ArticleId>
        <ArticleId IdType="pmc">PMC6127031</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cell Host Microbe. 2015 Jun 10;17(6):811-819</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26048136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10558-63</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22691496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Virol. 2014 May;88(10):5328-41</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24600004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncogene. 1999 Apr 1;18(13):2261-71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10327072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Lett. 2015 Nov 28;368(2):275-89</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25688671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Cell. 2010 Oct 8;40(1):63-74</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20932475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell. 2017 Nov 2;171(4):809-823.e13</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29056340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell. 2012 Aug 17;150(4):803-15</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22901810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Commun. 2017 Feb 10;8:14391</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28186168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nature. 2017 Oct 19;550(7676):402-406</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28976970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Biol Chem. 2009 May 22;284(21):14136-46</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19307177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elife. 2015 Dec 16;4:e11721</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26673078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Commun. 2016 Feb 19;7:10680</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26893169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curr Opin Immunol. 2018 Feb;50:82-87</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29247853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Science. 1998 Sep 11;281(5383):1674-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9733514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biochim Biophys Acta. 2016 Apr;1865(2):220-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26951863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nature. 2017 Aug 24;548(7668):461-465</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28738408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Host Microbe. 2015 Aug 12;18(2):157-68</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26235147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PLoS Pathog. 2016 Jul 07;12(7):e1005748</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27387064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Immunol. 2016 Sep 20;17(10):1142-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27648547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Commun. 2017 Feb 13;8:14392</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28194029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell. 2013 Aug 15;154(4):748-62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23910378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Cell Biol. 2017 Sep;19(9):1061-1070</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28759028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nucleic Acids Res. 2014 Jul;42(12):7666-80</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24928858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trends Immunol. 2017 Jan;38(1):39-52</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27863906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Gen Virol. 2012 Oct;93(Pt 10):2076-97</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22855786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Science. 2015 Mar 13;347(6227):aaa2630</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25636800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nature. 2017 Aug 24;548(7668):466-470</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28759889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncogene. 2003 Dec 4;22(55):8931-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14654789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Immunity. 2016 Sep 20;45(3):555-569</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27637147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Cell. 2009 Nov 13;36(3):365-78</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19917246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Cell. 2010 Oct 8;40(1):75-86</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20932476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Res. 2014 Apr 15;74(8):2182-92</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24737129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Cell Biochem. 2010 Jan 1;109(1):103-12</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19885868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell. 2017 Nov 16;171(5):1110-1124.e18</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29033128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Commun. 2017 Sep 5;8(1):427</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28874664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Immunol Rev. 2015 Jul;266(1):72-92</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26085208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Structure. 2011 Mar 9;19(3):418-29</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21397192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Immunol. 2010 Nov;11(11):997-1004</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20890285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):E62-71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24367117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):E3481-E3489</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28404732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Commun. 2016 Jun 21;7:11932</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27324217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Res. 2011 Jan;21(1):116-30</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21187855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bioessays. 2016 Jun;38(6):508-13</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27172878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Science. 1998 Sep 11;281(5383):1677-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9733515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carcinogenesis. 1993 May;14(5):833-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8504475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Cell Biol. 1988 Mar;106(3):761-71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2450098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Cell. 2014 Apr 24;54(2):289-96</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24766893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncogene. 2000 Dec 7;19(52):6033-42</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11146555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Rev Immunol. 2016 Dec;16(12):741-750</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27667712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E2058-E2067</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29440426</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">9417067</PMID>
      <DateCompleted>
        <Year>1998</Year>
        <Month>02</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0021-9258</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>273</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1998</Year>
              <Month>Jan</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of biological chemistry</Title>
          <ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro.</ArticleTitle>
        <Pagination>
          <MedlinePgn>215-21</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Hormone-sensitive lipase (HSL) is the rate-limiting enzyme in lipolysis. Stimulation of rat adipocytes with isoproterenol results in phosphorylation of HSL and a 50-fold increase in the rate of lipolysis. In this study, we used site-directed mutagenesis and two-dimensional phosphopeptide mapping to show that phosphorylation sites other than the previously identified Ser-563 are phosphorylated in HSL in response to isoproterenol stimulation of 32P-labeled rat adipocytes. Phosphorylation of HSL in adipocytes in response to isoproterenol and in vitro phosphorylation of HSL containing Ser --&gt; Ala mutations in residues 563 and 565 (S563A, S565A) with protein kinase A (PKA), followed by tryptic phosphopeptide mapping resulted in two tryptic phosphopeptides. These tryptic phosphopeptides co-migrated with the phosphopeptides released by the same treatment of F654HPRRSSQGVLHMPLYSSPIVK675 phosphorylated with PKA. Analysis of the phosphorylation site mutants, S659A, S660A, and S659A,S660A disclosed that mutagenesis of both Ser-659 and Ser-660 was necessary to abolish the activation of HSL toward a triolein substrate after phosphorylation with PKA. Mutation of Ser-563 to alanine did not cause significant change of activation compared with wild-type HSL. Hence, our results demonstrate that in addition to the previously identified Ser-563, two other PKA phosphorylation sites, Ser-659 and Ser-660, are present in HSL and, furthermore, that Ser-659 and Ser-660 are the major activity controlling sites in vitro.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Anthonsen</LastName>
            <ForeName>M W</ForeName>
            <Initials>MW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell and Molecular Biology, Section for Molecular Signaling, Lund University, S-221 00 Lund, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rönnstrand</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wernstedt</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Degerman</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Holm</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Biol Chem</MedlineTA>
        <NlmUniqueID>2985121R</NlmUniqueID>
        <ISSNLinking>0021-9258</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 3.1.1.13</RegistryNumber>
          <NameOfSubstance UI="D002787">Sterol Esterase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>L628TT009W</RegistryNumber>
          <NameOfSubstance UI="D007545">Isoproterenol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017667" MajorTopicYN="N">Adipocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015180" MajorTopicYN="N">Electrophoresis, Gel, Two-Dimensional</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007545" MajorTopicYN="N">Isoproterenol</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010449" MajorTopicYN="N">Peptide Mapping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002787" MajorTopicYN="N">Sterol Esterase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1998</Year>
          <Month>2</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1998</Year>
          <Month>2</Month>
          <Day>7</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1998</Year>
          <Month>2</Month>
          <Day>7</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">9417067</ArticleId>
        <ArticleId IdType="doi">10.1074/jbc.273.1.215</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
      <PMID Version="1">31511694</PMID>
      <DateRevised>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-4687</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>573</Volume>
            <Issue>7774</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature</Title>
          <ISOAbbreviation>Nature</ISOAbbreviation>
        </Journal>
        <ArticleTitle>SLC19A1 transports immunoreactive cyclic dinucleotides.</ArticleTitle>
        <Pagination>
          <MedlinePgn>434-438</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-019-1553-0</ELocationID>
        <Abstract>
          <AbstractText>The accumulation of DNA in the cytosol serves as a key immunostimulatory signal associated with infections, cancer and genomic damage
            <sup>1,2</sup>. Cytosolic DNA triggers immune responses by activating the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway
            <sup>3</sup>. The binding of DNA to cGAS activates its enzymatic activity, leading to the synthesis of a second messenger, cyclic guanosine monophosphate-adenosine monophosphate (2'3'-cGAMP)
            <sup>4-7</sup>. This cyclic dinucleotide (CDN) activates STING
            <sup>8</sup>, which in turn activates the transcription factors interferon regulatory factor 3 (IRF3) and nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB), promoting the transcription of genes encoding type I interferons and other cytokines and mediators that stimulate a broader immune response. Exogenous 2'3'-cGAMP produced by malignant cells
            <sup>9</sup> and other CDNs, including those produced by bacteria
            <sup>10-12</sup> and synthetic CDNs used in cancer immunotherapy
            <sup>13,14</sup>, must traverse the cell membrane to activate STING in target cells. How these charged CDNs pass through the lipid bilayer is unknown. Here we used a genome-wide CRISPR-interference screen to identify the reduced folate carrier SLC19A1, a folate-organic phosphate antiporter, as the major transporter of CDNs. Depleting SLC19A1 in human cells inhibits CDN uptake and functional responses, and overexpressing SLC19A1 increases both uptake and functional responses. In human cell lines and primary cells ex vivo, CDN uptake is inhibited by folates as well as two medications approved for treatment of inflammatory diseases, sulfasalazine and the antifolate methotrexate. The identification of SLC19A1 as the major transporter of CDNs into cells has implications for the immunotherapeutic treatment of cancer
            <sup>13</sup>, host responsiveness to CDN-producing pathogenic microorganisms
            <sup>11</sup> and-potentially-for some inflammatory diseases.
          </AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Luteijn</LastName>
            <ForeName>Rutger D</ForeName>
            <Initials>RD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Cell Biology, and Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zaver</LastName>
            <ForeName>Shivam A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology, University of Washington, Seattle, WA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gowen</LastName>
            <ForeName>Benjamin G</ForeName>
            <Initials>BG</Initials>
            <AffiliationInfo>
              <Affiliation>Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wyman</LastName>
            <ForeName>Stacia K</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garelis</LastName>
            <ForeName>Nick E</ForeName>
            <Initials>NE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Cell Biology, and Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Onia</LastName>
            <ForeName>Liberty</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Cell Biology, and Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McWhirter</LastName>
            <ForeName>Sarah M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Aduro Biotech, Berkeley, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Katibah</LastName>
            <ForeName>George E</ForeName>
            <Initials>GE</Initials>
            <AffiliationInfo>
              <Affiliation>Aduro Biotech, Berkeley, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Corn</LastName>
            <ForeName>Jacob E</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
              <Affiliation>Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zurich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Woodward</LastName>
            <ForeName>Joshua J</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology, University of Washington, Seattle, WA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raulet</LastName>
            <ForeName>David H</ForeName>
            <Initials>DH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Cell Biology, and Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, CA, USA. raulet@berkeley.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>09</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nature</MedlineTA>
        <NlmUniqueID>0410462</NlmUniqueID>
        <ISSNLinking>0028-0836</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>08</Month>
          <Day>08</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31511694</ArticleId>
        <ArticleId IdType="doi">10.1038/s41586-019-1553-0</ArticleId>
        <ArticleId IdType="pii">10.1038/s41586-019-1553-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">31578521</PMID>
      <DateRevised>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-4687</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2019</Year>
              <Month>Oct</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nature</Title>
          <ISOAbbreviation>Nature</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inducing and exploiting vulnerabilities for the treatment of liver cancer.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-019-1607-3</ELocationID>
        <Abstract>
          <AbstractText>Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies
            <sup>1,2</sup>; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma
            <sup>3</sup>. The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis)
            <sup>4,5</sup>. Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53. A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition
            <sup>6</sup> is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer.
          </AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Cun</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vegna</LastName>
            <ForeName>Serena</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Tumour Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Haojie</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Benedict</LastName>
            <ForeName>Bente</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Tumour Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lieftink</LastName>
            <ForeName>Cor</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ramirez</LastName>
            <ForeName>Christel</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Tumour Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Oliveira</LastName>
            <ForeName>Rodrigo Leite</ForeName>
            <Initials>RL</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morris</LastName>
            <ForeName>Ben</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gadiot</LastName>
            <ForeName>Jules</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Tumour Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>du Chatinier</LastName>
            <ForeName>Aimée</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Liqin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Dongmei</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Evers</LastName>
            <ForeName>Bastiaan</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Guangzhi</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xue</LastName>
            <ForeName>Zheng</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schepers</LastName>
            <ForeName>Arnout</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jochems</LastName>
            <ForeName>Fleur</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sanchez</LastName>
            <ForeName>Antonio Mulero</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mainardi</LastName>
            <ForeName>Sara</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Te Riele</LastName>
            <ForeName>Hein</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Tumour Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beijersbergen</LastName>
            <ForeName>Roderick L</ForeName>
            <Initials>RL</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qin</LastName>
            <ForeName>Wenxin</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. wxqin@sjtu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akkari</LastName>
            <ForeName>Leila</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Tumour Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. l.akkari@nki.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bernards</LastName>
            <ForeName>René</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands. r.bernards@nki.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nature</MedlineTA>
        <NlmUniqueID>0410462</NlmUniqueID>
        <ISSNLinking>0028-0836</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>08</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31578521</ArticleId>
        <ArticleId IdType="doi">10.1038/s41586-019-1607-3</ArticleId>
        <ArticleId IdType="pii">10.1038/s41586-019-1607-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>